Cullinan Therapeutics at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Cullinan Therapeutics brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on the future of T cell engagers and of antibody engineering more broadly. It covers engagers aimed at CD19 or BCMA as a new way to treat autoimmune diseases.

OrganizationPEGS Europe 2026 Attendance
cullinantherapeutics.com
Biotech
Biotech developing T cell engagers and other targeted therapies for autoimmune diseases and cancer.
Talk
Wed Nov 18
11:45am–12:15pm
Talk
Wed Nov 18
4:00pm–4:10pm
The Future of T Cell Engagers
Plenary
Bispecifics, multispecifics and T cell engagersOncology and immunotherapy
Panel
Wed Nov 18
4:10pm–4:50pm
Emerging Modalities and the Future of Antibody Engineering
Plenary · with Stanford University, University of Stuttgart, Johnson & Johnson Innovative Medicine
Protein and antibody engineering

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Cullinan Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction